New combo therapy shows promise for lymphoma in seniors
NCT ID NCT00690560
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 22 times
Summary
This study tested a two-step treatment for adults aged 65 to 80 with a type of lymphoma. First, they received standard chemotherapy plus a targeted antibody (rituximab). Then, they got more rituximab and a radioactive antibody (Y90 ibritumomab) to kill remaining cancer cells. The goal was to see if this approach could keep the cancer from coming back. 30 people took part, and the study is now complete.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Antoine Lacassagne
Nice, 06189, France
Conditions
Explore the condition pages connected to this study.